Table 5 Most common treatment-related adverse events
|  | All patients a | ≤ 40 mg OD b, c | 40 mg OD c | p value |
|---|---|---|---|---|
(CTCAE grade) | n = 343 n (%) | n = 206 n (%) | n = 137 n(%) | |
Rash | ||||
 • Any grade | 178 (51.9) | 110 (53.4) | 68 (49.6) | 0.495d |
 • ≥ G 3 | 11 (3.2) | 5 (2.4) | 6 (4.4) | 0.315d |
Dry skin | ||||
 • Any grade | 51 (14.9) | 27 (13.1) | 24 (17.5) | 0.261d |
 • ≥ G 3 | 0 | 0 | 0 | - |
Paronychia | ||||
 • Any grade | 121 (35.3) | 66 (32) | 55 (40.1) | 0.124d |
 • ≥ G 3 | 17 (5.0) | 7 (3.4) | 10 (7.3) | 0.103d |
Diarrhea | ||||
 • Any grade | 190 (55.4) | 104 (50.5) | 86 (62.8) | 0.027d |
 • ≥ G 3 | 12 (3.5) | 3 (1.5) | 9 (6.6) | 0.016e |
Stomatitis | ||||
 • Any grade | 88 (22.2) | 45 (21.8) | 43 (31.4) | 0.047d |
 • ≥ G 3 | 4 (1.2) | 1 (0.5) | 3 (2.2) | 0.306e |
GOT/GPT increase | ||||
 • Any grade | 28 (8.2) | 16 (7.8) | 12 (8.8) | 0.742d |
 • ≥ G 3 | 0 | 0 | 0 | - |